Exatecan
Alternative Names: DX 8951; DX 8951a; DX 8951f; Exatecan mesylateLatest Information Update: 16 Aug 2017
Price :
$50 *
At a glance
- Originator Daiichi Sankyo Company
- Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Biliary cancer; Breast cancer; Cervical cancer; Ewing's sarcoma; Gastric cancer; Haematological malignancies; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Rhabdomyosarcoma; Solid tumours